There can be variation in the licensing of
different medicines containing the same drug.
Oral solution
▶Sodium feredetate (Non-proprietary)
Iron (as Sodium feredetate) 5.5 mg per 1 ml SodiFer 190mg/5ml
oral solution sugar-free | 500 ml £12.07 DT = £14.95
▶Sytron (Forum Health Products Ltd)
Iron (as Sodium feredetate) 5.5 mg per 1 ml Sytron oral solution
sugar-free | 500 ml p £14.95 DT = £14.95
1.3 Megaloblastic anaemia
Anaemia, megaloblastic
Overview
Most megaloblastic anaemias result from a lack of either
vitamin B12 or folate, and it is essential to establish in every
case which deficiency is present and the underlying cause. In
emergencies, when delay might be dangerous, it is
sometimes necessary to administer both substances after the
bone marrow test while plasma assay results are awaited.
Normally, however, appropriate treatment should not be
instituted until the results of tests are available.
One cause of megaloblastic anaemia in the UK is pernicious
anaemia in which lack of gastric intrinsic factor resulting
from an autoimmune gastritis causes malabsorption of
vitamin B12.
Vitamin B12 is also needed in the treatment of
megaloblastosis caused by prolonged nitrous oxide
anaesthesia, which inactivates the vitamin, and in the rare
syndrome of congenital transcobalamin II deficiency.
Vitamin B12 should be given prophylactically after total
gastrectomy or total ileal resection (or after partial gastrectomy
if a vitamin B12 absorption test shows vitamin B12
malabsorption).
Apart from dietary deficiency, all other causes of vitamin B12
deficiency are attributable to malabsorption. There is little
place for the use of low-dose vitamin B12 orally and none for
vitamin B12 intrinsic factor complexes given by mouth.
Vitamin B12 in larger oral doses [unlicensed] may be
effective.
Hydroxocobalamin p. 1085 has completely replaced
cyanocobalamin p. 1085 as the form of vitamin B12 of choice
for therapy; it is retained in the body longer than
cyanocobalamin and thus for maintenance therapy can be
given at intervals of up to 3 months. Treatment is generally
initiated with frequent administration of intramuscular
injections to replenish the depleted body stores. Thereafter,
maintenance treatment, which is usually for life, can be
instituted. There is no evidence that doses larger than those
recommended provide any additional benefit in vitamin B12
neuropathy.
Folic acid below has few indications for long-term therapy
since most causes of folate deficiency are self-limiting or will
yield to a short course of treatment. It should not be used in
undiagnosed megaloblastic anaemia unless vitamin B12 is
administered concurrently otherwise neuropathy may be
precipitated.
In folate-deficient megaloblastic anaemia (e.g. because of
poor nutrition, pregnancy, or antiepileptic drugs), daily folic
acid supplementation for 4 months brings about
haematological remission and replenishes body stores.
For prophylaxis in chronic haemolytic states, malabsorption,
or in renal dialysis, folic acid is given daily or sometimes
weekly, depending on the diet and the rate of haemolysis.
Folic acid is also used for the prevention of methotrexate-
induced side-effects in severe Crohn’s disease, rheumatic
disease, and severe psoriasis.
Folinic acid p. 992 is also effective in the treatment of
folate deficient megaloblastic anaemia but it is generally
used in association with cytotoxic drugs; it is given as
calcium folinate.
There is no justification for prescribing multiple
ingredient vitamin preparations containing vitamin B12 or
folic acid.
For the use of folic acid before and during pregnancy, see
Neural tube defects (prevention in pregnancy) p. 1150.
VITAMINS AND TRACE ELEMENTS › FOLATES
PDF page 1106